

## EXHIBIT 97

1 UNITED STATES DISTRICT COURT  
2 FOR THE NORTHERN DISTRICT OF OHIO  
3 EASTERN DIVISION

4 IN RE: NATIONAL )  
5 PRESCRIPTION ) MDL No. 2804  
6 OPIATE LITIGATION )  
7 \_\_\_\_\_ ) Case No.  
8 ) 1:17-MD-2804  
9 )  
10 THIS DOCUMENT RELATES ) Hon. Dan A.  
11 TO ALL CASES ) Polster  
12 )

13 THURSDAY, APRIL 4, 2019

14 HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER  
15 CONFIDENTIALITY REVIEW

16 - - -

17 Videotaped deposition of Mark  
18 Geraci, held at the offices of DECHERT LLP,  
19 1095 Sixth Avenue, New York, New York,  
20 commencing at 9:10 a.m., on the above date,  
21 before Carrie A. Campbell, Registered  
22 Diplomate Reporter and Certified Realtime  
23 Reporter.

24 - - -

25 GOLKOW LITIGATION SERVICES  
26 877.370.3377 ph | 917.591.5672 fax  
27 deps@golkow.com

A P P E A R A N C E S :

SIMMONS HANLY CONROY, LLC

BY: JAYNE CONROY

jconroy@simmonsfirm.com

LAURA FITZPATRICK

lfitzpatrick@simmonsfirm.com

(VIA REALTIME STREAM)

ELLYN HURD

ehurd@simmonsfirm.com

SANFORD SMOKLER

(VIA REALTIME STREAM)

112 Madison Avenue, Seventh Floor

New York, New York 10016

(212) 784-6400

LANIER LAW FIRM, P.C.

BY: MILDRED CONROY

mildred.conroy@lanierlawfirm.com

126 East 56th Street, Sixth Floor

New York, New York 10022

(212) 421-2800

Counsel for Plaintiffs

DECHERT LLP

BY: NATHAN HOFFMANN

nathan.hoffman@dechert.com

DANA MARTIN

dana.martin@dechert.com

35 West Wacker Drive, Suite 3400

Chicago, Illinois 60601

(312) 646-5800

and

DECHERT LLP

BY: PAUL LAFATA

paul.lafata@dechert.com

1095 Avenue of the Americas

New York, New York 10036

(212) 698-3500

Counsel for Purdue Pharma

1 COVINGTON & BURLING LLP  
BY: SHAILEE DIWANJI SHARMA  
2 ssharma@cov.com  
850 Tenth Street, NW  
3 Washington, DC 20001-4956  
(202) 662-6000  
4 Counsel for McKesson Corporation  
5

6 JACKSON KELLY PLLC  
BY: JON L. ANDERSON  
7 jlanderson@jacksonkelly.com  
(VIA TELECONFERENCE)  
8 500 Lee Street East, Suite 1600  
Charleston, WV 25301-3202  
9 (304) 340-1288  
Counsel for AmerisourceBergen  
10  
11

VENABLE LLP  
12 BY: JOHN A. McCAULEY  
jamccauley@Venable.com  
13 (VIA TELECONFERENCE)  
750 East Pratt Street, Suite 900  
14 Baltimore, Maryland 21202  
(410) 244-7400  
15 Counsel for Abbott Laboratories  
16

17 VIDEOGRAPHER:  
HENRY MARTE,  
18 Golkow Litigation Services  
19

- - -

20  
21  
22  
23  
24  
25

1	INDEX		
2			PAGE
3	APPEARANCES.....		2
4	EXAMINATIONS		
5	BY MS. CONROY.....		8
6	BY MR. HOFFMAN.....		214
7	BY MS. CONROY.....		219
8			
9	EXHIBITS		
10	No.	Description	Page
11	Purdue	E-mail(s),	22
	Geraci 1	PPLPC022000763004 -	
12		PPLPC022000763005	
13	Purdue	"When OMS Started & Updated,"	36
	Geraci 2	PPLP004449246	
14			
	Purdue	Finance & Accounting Standard	96
15	Geraci 3	Operating Procedures Manual,	
		PPLPC004000119321_001 -	
16		PPLPC004000119321_003	
17	Purdue	Purdue Order Management System	102
	Geraci 4	SOP-0007,	
18		PPLP003430436 - PPLP003430441	
19	Purdue	Order Monitoring System (OMS),	121
	Geraci 5	PPLPC019001275418	
20			
	Purdue	CC-SOP-000017,	146
21	Geraci 6	PPLP004368538 - PPLP004368543	
22	Purdue	CC-SOP-000018,	146
	Geraci 7	PPLP004393084 - PPLP004393098	
23			
	Purdue	CC-SOP-000019,	146
24	Geraci 8	PPLPC023000971890 -	
		PPLPC023000971896	
25			

1	Purdue	E-mail(s) ,	161
	Geraci 9	PPLPC00400317960 -	
2		PPLPC00400317961	
3	Purdue	Objection to Notice of	219
	Geraci 10	Deposition	
4			
	Purdue	Notice of Deposition Pursuant	226
5	Geraci 11	to Rules 30(B)(6) and Document	
		Request Pursuant to Rule	
6		30(B)(2) and Rule 34 to Purdue	
		Pharma, L.P., Purdue Pharma,	
7		Inc., and the Purdue Frederick	
		Company	
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			

1 VIDEOGRAPHER: Okay. We are  
2 now on the record. My name is Henry  
3 Marte. I'm a videographer with Golkow  
4 Litigation Services.

5 Today's date is April 4, 2019,  
6 and the time is 9:10 a.m.

7 This videotaped deposition is  
8 being held at 1095 Avenue of the  
9 Americas, New York, New York, in the  
10 matter of National Prescription Opiate  
11 Litigation.

12 The deponent today is Mark  
13 Geraci.

14 All appearances please  
15 introduce themselves for the record.

16 MS. CONROY: Jayne Conroy for  
17 plaintiffs.

18 MS. HURD: Ellyn Hurd for  
19 plaintiffs.

20 MS. CONROY: Mildred Conroy,  
21 Lanier Law Firm, for the plaintiffs.

22 MR. HOFFMAN: Nathan Hoffman on  
23 behalf of the Purdue defendants and  
24 the witness.

25 MR. LAFATA: Paul LaFata from

1 Dechert for the Purdue defendants  
2 also.

3 MS. MARTIN: Dana Martin from  
4 Dechert for the Purdue defendants  
5 also.

6 MS. SHARMA: Shailee Diwanji  
7 Sharma, Covington & Burling, for  
8 McKesson.

9 VIDEOGRAPHER: And those on the  
10 phone, please?

11 MR. ANDERSON: Jon Anderson,  
12 Jackson Kelly, on behalf of  
13 AmerisourceBergen.

14 MR. McCAULEY: John McCauley  
15 for Abbott.

16 VIDEOGRAPHER: Anyone else?

17 Okay. Will the court reporter  
18 please administer the oath to the  
19 witness.

20  
21 MARK GERACI,  
22 of lawful age, having been first duly sworn  
23 to tell the truth, the whole truth and  
24 nothing but the truth, deposes and says on  
25 behalf of the Plaintiffs, as follows:



1 DIRECT EXAMINATION

2 QUESTIONS BY MS. CONROY:

3 Q. Good morning, Mr. Geraci.

4 A. Ms. Conroy.

5 Q. Have you ever had your  
6 deposition taken before?

7 A. No.

8 Q. Was that a no?

9 A. No.

10 Q. Okay. A couple of ground  
11 rules. We have a court reporter, which you  
12 saw her magic machine a moment ago, and so  
13 she's going to take down what I say; she's  
14 going to take down what you say. It's hard  
15 if we talk at the same time, so try to wait  
16 for the end of my question, and I'll try not  
17 to start a question during your answer.

18 Okay?

19 A. Fine.

20 Q. If you want to take a break at  
21 any point, just let me know. I would prefer  
22 you not take one between a question and  
23 answer; we'll wait until the answer is  
24 completed to take a break. And we'll all try  
25 to remind ourselves to remove our microphones

1 before we break.

2 A. Okay.

3 Q. But you're allowed one break  
4 without removing it.

5 Where do you live?

6 A. In New York state.

7 Q. And did you prepare at all for  
8 this deposition today?

9 A. Yes.

10 Q. Okay. Did you meet with your  
11 lawyers?

12 A. Yes.

13 Q. Okay. Who did you meet with?

14 A. Nathan, Paul and Dana.

15 Q. And for approximately how long?

16 A. Five to six hours in total.

17 Q. And did you review any  
18 documents in preparation for this deposition?

19 A. Yes.

20 Q. And were those documents that  
21 you had in your possession, or were they  
22 provided to you?

23 A. They were provided to me.

24 Q. Okay. Were any of the  
25 documents that you reviewed in your

1 possession?

2 A. No.

3 Q. And did you review those  
4 documents separately from the meetings that  
5 you had with Nathan, Paul and Dana?

6 MR. HOFFMAN: Object to the  
7 form.

8 To the extent counsel provided  
9 it to him, I don't think there's any  
10 distinction there, but go ahead.

11 QUESTIONS BY MS. CONROY:

12 Q. Well, I'm asking about when you  
13 reviewed them.

14 Did you review them during the  
15 time you were meeting with your lawyers, or  
16 was it a separate period of time that you  
17 reviewed the documents?

18 A. Both.

19 Q. Okay. And approximately how  
20 much time did you spend reviewing the  
21 documents outside the presence of your  
22 lawyers?

23 A. Maybe an hour.

24 Q. What's your current title at  
25 Purdue?

1           A.       I am vice president and chief  
2 security officer.

3           Q.       VP and chief security officer.  
4                   What are your responsibilities  
5 in that role?

6           A.       I am responsible for the  
7 protection of the company's people, its  
8 facilities, its information.

9                   That's in the broadest sense.

10          Q.       And for how long have you held  
11 that position?

12          A.       I've been with Purdue for ten  
13 years.

14          Q.       And have you been a vice  
15 president and chief security officer for the  
16 ten years?

17          A.       Yes.

18          Q.       Have you had any promotions or  
19 job title changes in the ten years?

20          A.       No.

21          Q.       How about responsibilities,  
22 have they changed over the ten years?

23          A.       Yes.

24          Q.       In what way?

25          A.       Currently I'm chairman of the

1 executive audit committee.

2 Q. And what does the executive  
3 audit committee do, or what are your  
4 responsibilities on that committee?

5 A. We coordinate the activities of  
6 our external auditors and our internal  
7 auditors.

8 Q. Any other responsibilities that  
9 have changed over the ten years?

10 A. Yes.

11 I don't recall when it  
12 occurred, but the control substance act group  
13 based out of our North Carolina facilities  
14 was moved from the legal division into  
15 corporate security.

16 Q. The North Carolina facility,  
17 what does that facility do?

18 A. That's a manufacturing  
19 facility.

20 Q. Okay. And what did the CSA  
21 group do, roughly, generally, at that  
22 manufacturing facility?

23 A. Primary mandate is to be  
24 DEA-ready, for inspection by the DEA.

25 Q. And that group was moved?

1 A. Yes.

2 Q. Off site?

3 A. No. Moved from where it  
4 reported in to.

5 Q. Oh, I see. I see.

6 So they remain in North  
7 Carolina --

8 A. Yes.

9 Q. -- but they report to you?

10 A. They did, yes, that's correct.

11 Q. They did. Okay.

12 And is that no longer the case?

13 A. That is not the case now.

14 Q. Okay. And for how long has  
15 that not been the case?

16 A. The change occurred last year.

17 Q. Do they report to someone else?

18 A. They report locally, into local  
19 operations, with oversight by corporate  
20 security.

21 Q. Any other changes in  
22 responsibilities?

23 A. No.

24 Q. Did you -- at some point you  
25 became a member of the order monitoring

1 committee at Purdue?

2 A. Yes.

3 Q. Okay. And did that start when  
4 you began at Purdue?

5 A. Yes.

6 Q. And has that remained the case?

7 A. Yes.

8 Q. Where were you before Purdue?

9 A. I was with Bristol-Myers  
10 Squibb, BMS, as you probably -- as I see you  
11 writing down here.

12 Q. And what was -- what were  
13 your -- what was generally your title and  
14 your responsibilities there?

15 A. I was the senior director of  
16 corporate security with worldwide  
17 responsibility. Same three broad bullets of  
18 responsibility.

19 Q. Okay. And where were you  
20 located?

21 A. Here in New York City.

22 Q. And where is your office at  
23 Purdue, if you have an office?

24 A. Stamford, Connecticut.

25 Q. And is that where you go to

1 work every day?

2 A. Yes.

3 Q. And has that been the case for  
4 the ten years?

5 A. Yes.

6 Q. For how long were you at BMS?

7 A. Over 27 years.

8 Q. So I take it your roles changed  
9 and expanded over those 27 years?

10 A. Yes.

11 Q. And could you describe for me  
12 briefly why you left BMS and went to Purdue  
13 ten years ago?

14 A. It was an opportunity to  
15 actually be the leader of the entire group,  
16 corporate security.

17 Q. And you described BMS as a -- I  
18 think did you say international --

19 A. No, I did not.

20 Q. How did you describe it?

21 A. I said my responsibilities were  
22 global.

23 Q. Global. Oh, sorry.

24 What is the range of your  
25 responsibilities at Purdue geographically?



1 A. United States.

2 Q. Is there someone -- is there  
3 anyone in Connecticut that is responsible for  
4 outside of the United States in a corporate  
5 security capacity?

6 A. No.

7 Q. And what facilities in the  
8 United States do you oversee in your role as  
9 VP and corporate security chief?

10 A. We have our corporate  
11 headquarters and our two manufacturing  
12 locations in North Carolina.

13 Q. What about Rhodes in Rhode  
14 Island?

15 A. No direct responsibility for  
16 Rhodes.

17 Q. Do you have any indirect  
18 responsibilities for Rhodes?

19 A. On occasion, providing  
20 consultation and advice.

21 Q. Is there someone in a role  
22 comparable to yours at Rhodes?

23 A. There is a security manager at  
24 Rhodes.

25 Q. Prior to BMS -- long time

1       ago --

2               A.       Yes.    Yes, it was.

3               Q.       -- where were you?

4               A.       I was a special investigator  
5       with the New York State Attorney General's  
6       Office.

7               Q.       And what was your concentration  
8       there or what did you investigate?

9               A.       Criminal investigations of  
10       health care fraud at hospitals, nursing homes  
11       and eventually Medicaid, all Medicaid fraud,  
12       throughout the state.

13              Q.       And how long were you there?

14              A.       I was there four years.

15              Q.       What sort of fraud did you  
16       investigate?  You can give me some examples.

17              A.       Health care fraud.  It was  
18       basically white collar crime.

19              Q.       Okay.  Did you investigate  
20       doctors?

21              A.       Yes.

22              Q.       Did you investigate  
23       pharmaceutical companies?

24              A.       No.

25              Q.       What about distributors or

1 anyone in the supply chain of a  
2 pharmaceutical --

3 A. No.

4 Q. -- company?

5 A. No.

6 MR. HOFFMAN: Just wait until  
7 she finishes her question.

8 QUESTIONS BY MS. CONROY:

9 Q. And prior to the New York State  
10 Attorney General's Office, where were you?

11 A. I was at university.

12 Q. Okay. And which university?

13 A. I graduated in -- at Florida  
14 Atlantic University.

15 Q. And what year was that that you  
16 graduated?

17 A. 1977.

18 Q. And what was your degree?

19 A. Criminal justice.

20 Q. Do you have any degrees  
21 after -- was that a BA or a BS?

22 A. BA.

23 Q. Any degrees after the BA?

24 A. Yes.

25 Q. And what are they?

1           A.       I have a bachelor's degree in  
2     accounting.

3           Q.       And where did you receive that  
4     degree?

5           A.       New York -- SUNY Empire State  
6     College.

7           Q.       And when?

8           A.       1981.

9           Q.       Any other degrees?

10          A.       I have an MBA.

11          Q.       And year?   What year did you  
12     receive that?

13          A.       1984.

14          Q.       And whereabouts?

15          A.       New York Institute of  
16     Technology.

17          Q.       And any other degrees?

18          A.       No.

19          Q.       Do you have any certifications  
20     of any sort?

21          A.       Yes.

22          Q.       What are they?

23          A.       I have a CPP, which is  
24     designated by ASIS International, which is  
25     the largest security association in the

1 world.

2 Q. And what is that -- what does  
3 that certification suggest to the world?

4 A. That you're a professional,  
5 certified protection professional.

6 Q. And what is involved in  
7 receiving that certification?

8 A. Examination.

9 Q. And when did you first take  
10 that examination?

11 A. Oh, gee.

12 Q. Or if you want to give me like  
13 where you were or --

14 A. I'm thinking it was 1996, '97.

15 Q. And is that something that you  
16 just take once, or do you have to renew it  
17 over time?

18 A. You have to take continuing  
19 education.

20 Q. And have you done that? Have  
21 you kept up with it?

22 A. Yes.

23 Q. Any other certifications?

24 A. I am a certified fraud  
25 examiner.

1 Q. And when did you receive that  
2 certification?

3 A. I don't recall.

4 Q. Would it have been prior to  
5 your New York State employment?

6 A. No.

7 Q. And are you current as a  
8 certified fraud examiner?

9 A. Yes, I am.

10 Q. And any other certifications?

11 A. No.

12 Q. Do you teach at all?

13 A. Not currently.

14 Q. Have you taught in the past?

15 A. Yes.

16 Q. What have you taught?

17 A. What was it? Corporate  
18 security. Corporate security.

19 Q. Okay. And where did you do  
20 that?

21 A. Suffolk County Community  
22 College in New York.

23 Q. Out on Long Island?

24 A. That is correct.

25 Q. And for how long did you do

1       that?

2               A.       I believe two semesters.

3               Q.       And how long ago was that,  
4       approximately?

5               A.       Over ten years ago.

6               Q.       So while you were at BMS?

7               A.       That is correct.

8               Q.       Any other teaching engagements?

9               A.       No.

10              Q.       And do you ever participate as  
11      an instructor in CLE?

12              A.       No.

13              Q.       Have you ever published any  
14      articles or books or book chapters with  
15      respect to any of your employment  
16      responsibilities?

17              A.       No.

18              Q.       Any in the works?

19              A.       No.



























































































































































































1 Are you familiar at all with  
2 the procedures in the national accounts  
3 department with respect to the receipt of  
4 orders from distributors or wholesalers with  
5 respect to triggering a suspicious order  
6 because of size, frequency or pattern?

7 MR. HOFFMAN: Objection.

8 QUESTIONS BY MS. CONROY:

9 Q. That's before the order is  
10 filled.

11 MR. HOFFMAN: Sorry.

12 QUESTIONS BY MS. CONROY:

13 Q. Are you familiar with that  
14 trigger?

15 MR. HOFFMAN: Sorry. Object to  
16 form.

17 THE WITNESS: No.

18 QUESTIONS BY MS. CONROY:

19 Q. Did you understand what I was  
20 talking about?

21 A. Yes.

22 Q. And then I take it you have  
23 never had any conversations with Stephen Seid  
24 or Mr. Berjanski {phonetic} about suspicious  
25 order triggers when the order actually comes

1 into Purdue before the order is filled?

2 A. I don't recall having specific  
3 discussions with Mr. Seid or Mr. Berjanski  
4 about that.

5 Q. Okay. Do you recall any  
6 conversations with anyone about that?

7 A. I don't recall any specific  
8 conversations.

9 Q. Do you recall ever generally  
10 discussing the concept of there being a  
11 trigger with respect to the size, frequency  
12 or pattern of an order that is received by  
13 Purdue?

14 A. I recall discussion at  
15 committee meetings where this would be  
16 discussed.

17 Q. And what do you recall about  
18 that?

19 A. That this group, national  
20 account group, would -- that there was a  
21 review that would be conducted of orders at  
22 their level looking for large or unusual  
23 orders during any given time.

24 Q. And was there any discussion  
25 about what was done with those orders,

1       whether they were filled or not?

2               A.       I don't recall any specific  
3       discussions about that.

4               Q.       Was there any discussion about  
5       the connection between filling the order to  
6       the distributor and pharmacies of suspicion  
7       that that distributor was supplying?

8               MR. HOFFMAN:   Object to form.

9               THE WITNESS:   I don't recall  
10       any specific discussions.










































































































4 MR. HOFFMAN: Jayne, for your  
5 planning purposes, I think we're  
6 having lunch set up at like 12:15. So  
7 it's in another 20-something minutes.  
8 If that's okay with you guys.

9 MS. CONROY: That's great.  
10 Thank you.

11 How are you doing? Do you  
12 want --

13 THE WITNESS: I'm fine.

14 MS. CONROY: Okay. We'll  
15 keep -- we'll just keep going?

16 MR. HOFFMAN: Sure.

17 MS. CONROY: You tell me when  
18 lunch is here. Or tell me when it's  
19 12:20.





7 MS. CONROY: I'll try and do it  
8 in order. That would actually make  
9 more sense.

10 THE WITNESS: While you're  
11 doing that, may I just step out for a  
12 second? Thank you.

13 MS. CONROY: We'll go off the  
14 record.

15 VIDEOGRAPHER: The time is  
16 11:54 a.m. Off the record.


17 (Off the record at 11:54 a.m.)

18 VIDEOGRAPHER: Okay. We are  
19 back on the record. The time is  
20 11:59 a.m.

21 (Purdue-Geraci Exhibits 6, 7  
22 and 8 marked for identification.)















9 Do you know if the order  
10 monitoring committee has been suspended, or  
11 do you know if it ceases to exist?

12 MR. HOFFMAN: Object to the  
13 form.

14 THE WITNESS: The order  
15 monitoring committee continues.

16 QUESTIONS BY MS. CONROY:

17 Q. Have you had any meetings?

18 A. I don't know if they've had any  
19 meetings.

20 Q. Okay. Do you believe you're  
21 still on the order monitoring committee?

22 A. I don't -- there isn't a  
23 committee as such as it was before, so to  
24 answer your question, I -- I really haven't  
25 given thought as to if I'm on the committee

1 or not.

2 Q. Okay. Let me ask it this way:  
3 Do you know if there -- do you know if  
4 there's still an order monitoring committee  
5 but it's a different committee and under a  
6 different oversight department, or is it the  
7 same order monitoring committee, you just  
8 don't know if it's active?

9 A. I just testified that it still  
10 exists. It is active. It is within the  
11 corporate ethics and compliance group.

12 Q. Did you say it is within the  
13 corporate --

14 A. It is within.

15 Q. The corporate ethics and  
16 compliance?

17 A. Yes.

18 Q. But you have not, to the best  
19 of your knowledge, attended any meetings?

20 A. I have not attended any  
21 meetings to the best of my knowledge.

22 Q. Okay. Do you receive any  
23 packages or agendas or anything like that  
24 with respect to the order monitoring  
25 committee now that it's part of corporate

1 ethics and compliance?

2 A. I have not, to the best of my  
3 recollection.

4 Q. What about Mr. Bauza, do you  
5 know if he has attended any meetings or if he  
6 receives any materials?

7 A. I don't know.

8 Q. How do you know it's still  
9 active?

10 A. In my discussions with Maggie  
11 Feltz, and in discussions I've had with Eric  
12 Brantley over time.

13 Q. Do you know who the other  
14 committee members are once there was the  
15 switch to corporate ethics?

16 A. The committee members were  
17 those individuals listed on the -- I think  
18 they call this their SOP, right?

19 Q. Right.

20 A. Yes. Corporate compliance  
21 CC-SOP. It would be those individuals.

22 Q. Danielle --

23 A. Eric Brantley, Danielle Bacco,  
24 Margaret Feltz, Alexis Stroud.

25 Q. Do you know if anyone from

1 national accounts is still on the order  
2 monitoring committee?

3 A. I don't know.

4 Q. Do you know if anyone from  
5 marketing or sales, the marketing and sales  
6 side of the business, is on the order  
7 monitoring committee?

8 A. I don't know.

9 Q. Do you know if anyone from the  
10 legal department is on the order monitoring  
11 committee?

12 A. I don't know.

13 Q. Do you know if it's only those  
14 four individuals, or do you know one way or  
15 the other if there are additional members on  
16 the committee?

17 A. I don't know if there are  
18 additional members.

19 Q. Do you know if you are -- let  
20 me ask it this way: Would you have been  
21 familiar with or had in your possession, for  
22 example, the SOP with respect to ADD, abuse,  
23 diversion and detection? Would that be  
24 something that you would have -- you would  
25 have had in your role as a member of the

1 order monitoring committee?

2 A. That I would have had what?

3 I'm sorry, Ms. Conroy.

4 Q. The SOP, for example, the ADD  
5 reports.

6 A. I don't recall ever having the  
7 SOP for the ADD or anything related to ADD.

8 Q. Did you ever even know that  
9 there was an SOP for the ADD reporting?

10 A. Did I ever know? No, I don't  
11 know.

12 Q. Okay. Did you ever know one  
13 way or the other whether there was an SOP for  
14 reports of concern?

15 A. I don't know or ever recall  
16 being aware of an SOP for reports of concern.

17 Q. So that's not something you  
18 would have had in your possession, such an  
19 SOP, or if you had it, you didn't know what  
20 it was?

21 A. Well, I'll answer that I don't  
22 know that I ever had those in my possession,  
23 those SOPs.

24 Q. What about a Fee-For-Service  
25 SOP, is that familiar to you at all? Would

1       you have ever seen one of those?

2               A.       I don't recall ever seeing a  
3       Fee-For-Service SOP.

4               Q.       Do you know if you even knew if  
5       one existed?

6               A.       I did not know that one  
7       existed.

8               Q.       Okay. Generally at Purdue --  
9       or let me ask it this way: In your role as  
10      corporate security, do you work -- do you and  
11      the individuals who report to you operate  
12      under SOPs or refer to SOPs for their sort of  
13      daily functions?

14              MR. HOFFMAN: Object to the  
15      form.

16              THE WITNESS: Corporate  
17      security has certain SOPs that are  
18      very specific, but not to your daily  
19      function. Not that I know of to daily  
20      function. Pretty much in the roles  
21      and responsibilities. Physical  
22      security, for example.

23      QUESTIONS BY MS. CONROY:

24              Q.       And are you involved in the  
25      drafting or review of those SOPs that relate

1 to corporate security?

2 A. I would have been when those  
3 things -- during my tenure if those things  
4 were up for review or for drafting, I would  
5 have reviewed those and approved those.

6 Q. And is there a department at  
7 Purdue that keeps track of SOPs that makes  
8 sure that they are kept up to date and they  
9 keep a record of that sort of thing?

10 MR. HOFFMAN: Object to the  
11 form. Beyond the scope.

12 THE WITNESS: Yeah, I don't  
13 know if there's a department that has  
14 it. I assume that they reside  
15 someplace.

16 QUESTIONS BY MS. CONROY:

17 Q. When you have a new employee  
18 come in to corporate security, are they given  
19 the SOPs for that -- for the corporate  
20 security department?

21 MR. HOFFMAN: Object to the  
22 form.

23 THE WITNESS: No.

24 MR. HOFFMAN: Beyond the scope.

25 THE WITNESS: Yeah, I haven't

1           had a new employee in a long time. I  
2           don't recall.

3           QUESTIONS BY MS. CONROY:

4           Q.       Okay. Would you, for example,  
5           have copies or know where to puts your hands  
6           on the SOPs that relate to corporate  
7           security?

8           A.       I would know who to ask to get  
9           those.

10          Q.       Is it part of Purdue as a  
11          corporation's culture to have SOPs that sort  
12          of guide or explain in general the  
13          responsibilities and duties of the different  
14          departments?

15                   MR. HOFFMAN: Object to the  
16                   form. Beyond the scope.

17                   THE WITNESS: To the best of my  
18                   knowledge, we -- there are a number of  
19                   SOPs that various departments, if not  
20                   all departments, have, to the extent  
21                   of which I don't know.

22          QUESTIONS BY MS. CONROY:

23          Q.       Compared to an SOP, for  
24          example, do you have a guidebook or anything  
25          like that for corporate security or would it



1 be the SOPs?

2 A. We do not have a guidebook, per  
3 se.

4 Q. Do you have something like a  
5 guidebook?

6 A. As I recall, there may be some  
7 references to, quote, security in our  
8 employee handbooks, but it's broad and  
9 general, just for the employee base.

10 Q. Okay. With respect to the  
11 order monitoring committee, we looked at the  
12 SOP that specifically concerned the order  
13 monitoring committee, correct?

14 A. Yes, we did.

15 Q. Are you familiar with any other  
16 guidelines, handbooks, anything else that you  
17 would have referred to as a member of the  
18 order monitoring committee to define your  
19 responsibilities or outline your  
20 responsibilities or lay out protocols,  
21 anything like that, or would it be the SOP?

22 A. I'm unaware of any other SOP or  
23 guidelines that would have guided our -- how  
24 we comported ourselves with regard to the  
25 order monitoring.

1 MS. CONROY: Okay. I think we  
2 can break for lunch. We just saved a  
3 lot of time.

4 THE WITNESS: Great. Good.

5 VIDEOGRAPHER: Off the record,  
6 right? The time is 12:16 p.m. Off  
7 the record.

8 (Off the record at 12:16 p.m.)

9 VIDEOGRAPHER: Okay. We are  
10 back on the record. The time is  
11 1:16 p.m.























































































20 Are you familiar with the

21 entities ValuTrack or ValueCentric?

22 A. I've heard the names.

23 Q. If I suggested to you they had

24 something to do with the collection of

25 Fee-For-Service data, would that refresh your

1 memory at all?

2 A. It sounds reasonable.

3 Q. What about the either software,  
4 a database or an entity known as Vinyl? Is  
5 that familiar to you at all?

6 A. Yes.

7 Q. And what is that?

8 A. As I recall, it's a software  
9 that was used to capture information so --  
10 for easier retrieval, whether it be reports  
11 of concern -- and I'm not sure if  
12 Fee-For-Service data was in there, but that's  
13 what I recall. It was a better way of  
14 tracking information and being able to  
15 retrieve that information.

16 Q. Okay. Is it still in effect?  
17 Do you know?

18 A. I don't know.

19 Q. Can you put a time frame on it?  
20 Would it have been at the time  
21 that legal was responsible at the order  
22 monitoring committee, or compliance?

23 A. I don't recall. I don't  
24 recall.

25 Q. Are you familiar at all with

1 scorecards that are kept by national accounts  
2 with respect to particular -- with respect to  
3 all of the authorized distributors?

4 A. No.

5 Q. You're not familiar with that  
6 term "scorecards"?

7 A. For distributors, no.

8 Q. Okay. Are you familiar with it  
9 for pharmacies?

10 A. No.

11 Q. Have you heard of the entity  
12 Edge Dynamics?

13 A. No, I have not.





16           Q.       Did you ever see any board  
17       packages or have any discussions at the -- or  
18       not board -- committee packages or have any  
19       discussions at the order monitoring committee  
20       about any CVS stores?

21           A.       I don't recall any discussions  
22       about any particular chains, including CVS.

23           Q.       Do you know why there wouldn't  
24       have been any discussion about chains?

25           A.       No.

1 MR. HOFFMAN: Object to the  
2 form.

3 THE WITNESS: No, I don't.

4 QUESTIONS BY MS. CONROY:

5 Q. Do you know whether the  
6 individual data with respect to the actual  
7 chain pharmacy at a particular street address  
8 was available in the Fee-For-Service data?

9 A. I assume that it was.

10 Q. Did it ever -- did it ever come  
11 up as an issue that the chain pharmacies did  
12 not appear in conversations at the order  
13 monitoring committee?

14 MR. HOFFMAN: Object to the  
15 form.

16 THE WITNESS: I don't recall.

17 QUESTIONS BY MS. CONROY:

18 Q. But you do recall that -- you  
19 don't recall there ever being a discussion  
20 about one of the chain pharmacies at an order  
21 monitoring committee meeting?

22 A. I don't recall.

23 Q. You don't --

24 A. I don't recall a discussion  
25 about a chain pharmacy at an OMS meeting.

1 Q. Okay. Thank you.

2 Do you believe that Purdue had  
3 as much data as their authorized distributors  
4 with respect to the outlets or the  
5 pharmacies?

6 MR. HOFFMAN: Object to the  
7 form.

8 THE WITNESS: I can't judge  
9 that because I don't know what the  
10 distributors actually had.

11 QUESTIONS BY MS. CONROY:

12 Q. Was there anything that you  
13 believed Purdue was missing with respect to  
14 pharmacy data that it was receiving from the  
15 distributors?

16 MR. HOFFMAN: Object to the  
17 form. Calls for speculation.

18 THE WITNESS: It never -- I  
19 never thought of any particular  
20 information that was not forthcoming  
21 to us based on what we were requiring  
22 from the distributors.

23 QUESTIONS BY MS. CONROY:

24 Q. So you yourself never  
25 identified any gaps or areas where you would

1 like more information?

2 A. More information from whom?

3 Q. From the -- from your customer,  
4 the distributor.

5 A. I don't recall that ever coming  
6 up or me thinking there was a gap.

7 Q. Right.

8 A. I don't recall that happening.

9 Q. Okay. Would you agree that at  
10 least as long as you were involved in the  
11 order monitoring committee that Purdue has no  
12 quantifiable trigger that identifies an order  
13 as suspicious and would require a referral to  
14 DEA?

15 MR. HOFFMAN: Object to form.  
16 Beyond the scope.

17 THE WITNESS: Would you  
18 rephrase the question, please?

19 QUESTIONS BY MS. CONROY:

20 Q. Well, I'll tell you what, I'll  
21 try or -- I'll reask it.

22 Do you know if Purdue has a  
23 quantifiable trigger that would automatically  
24 require Purdue to refer to the DEA a  
25 suspicious customer?

1 MR. HOFFMAN: Object to form.

2 Time frame and beyond the scope.

3 THE WITNESS: I do not know if  
4 we have an -- a quantifiable automatic  
5 trigger, and there's none to the best  
6 of my knowledge.

7 QUESTIONS BY MS. CONROY:

8 Q. And so far as you know, the  
9 order monitoring committee must be involved  
10 in order to reach a determination to refer a  
11 suspicious pharmacy or outlet to the DEA?

12 MR. HOFFMAN: Object to form.

13 THE WITNESS: Order monitoring  
14 committee or system would be -- has to  
15 be involved --

16 QUESTIONS BY MS. CONROY:

17 Q. Right.

18 A. -- for pharmacy referrals to  
19 the DEA.

20 Q. Or at least that's how you  
21 understand it works. There would be a  
22 determination by the members of the order  
23 monitoring committee to refer to DEA?

24 A. That is correct.

25 Q. Are you aware of any time

1 restrictions based on ongoing investigations  
2 of suspicious pharmacies or customers at  
3 Purdue?

4 MR. HOFFMAN: Object to the  
5 form.

6 THE WITNESS: I'm not aware of  
7 any time restrictions.

8 QUESTIONS BY MS. CONROY:

9 Q. So for as long as the order  
10 monitoring committee decides to investigate a  
11 pharmacy, there's no cutoff of that; they can  
12 continue to investigate as long as they see  
13 fit?

14 A. I'm unaware of any time  
15 restriction.

16 Q. Is it true that if a  
17 distributor's customer was deemed to be  
18 suspicious, at least by triggering the  
19 algorithm, that a distributor could just --  
20 in a conversation with a member of the order  
21 monitoring committee could justify that or  
22 explain why such an order took place or  
23 whatever to dispel the suspicion?

24 MR. HOFFMAN: Object to form.

25 THE WITNESS: It's my

1           understanding that there -- in that  
2           conversation, if it was had and when  
3           it was had, that they could provide,  
4           the distributor could provide,  
5           justification or an explanation that  
6           may explain the anomaly in the orders.

7                       That information then would be  
8           presented to the OMS team for  
9           consideration.

10       QUESTIONS BY MS. CONROY:

11           Q.       Do you know if that information  
12       needed to be in writing or could it be  
13       relayed to one of the -- to the order  
14       monitoring committee members and then  
15       expressed at the committee meeting, or did it  
16       need -- did that justification or explanation  
17       need to be in writing from the distributor or  
18       from the pharmacy?

19           A.       Yeah, I don't believe it needed  
20       to be in writing.

21           Q.       Okay. I don't know if you know  
22       the answer to this, but let me ask it anyway.

23                       With respect to any electronic  
24       records with respect to the OMS work or lists  
25       of suspicious pharmacies or whatever, do you

1 know if someone went in and searched that  
2 database if those -- if logs of searches were  
3 retained?

4 A. I have no knowledge of that.

5 Q. Okay. And likewise, do you  
6 know whether or not it was possible to  
7 overwrite electronic notes in the OMS  
8 database? Do you know one way or the other?

9 A. I don't know.

10 Q. Do you know one way or the  
11 other whether there is any centralized  
12 repository for queries that were made into or  
13 of the order monitoring database?

14 MR. HOFFMAN: I'll just object  
15 to form. I think all of these are  
16 beyond the scope.

17 But go ahead, if you know.

18 THE WITNESS: I don't know.

19 QUESTIONS BY MS. CONROY:

20 Q. Do you believe there's an  
21 opioid crisis in this country?

22 MR. HOFFMAN: Objection.  
23 Beyond the scope.

24 THE WITNESS: Yes, there is  
25 an -- I do believe there's an opioid



1 crisis.

2 QUESTIONS BY MS. CONROY:

3 Q. Do you believe that the order  
4 monitoring committee and the role it played  
5 was successful?

6 MR. HOFFMAN: Object to form.

7 THE WITNESS: I believe that  
8 the order monitoring committee, that  
9 the good work and the evolution of  
10 that committee to do its job better  
11 and better and more efficiently, was  
12 successful to a certain extent. It --  
13 there were referrals to the DEA, and  
14 we considered that a very positive  
15 step and a good thing to do.

16 So there's a certain -- certain  
17 measure of success there as far as I'm  
18 concerned.

19 QUESTIONS BY MS. CONROY:

20 Q. Okay. And is that how you  
21 measure the success of the order monitoring  
22 committee, the referrals to DEA?

23 MR. HOFFMAN: Object to form.

24 Beyond the scope.

25 THE WITNESS: I could see that

1 as being a measure of success.

2 QUESTIONS BY MS. CONROY:

3 Q. Any other measures that you can  
4 see?

5 MR. HOFFMAN: Same objection.

6 THE WITNESS: I would say over  
7 time that the measure of success is  
8 how we -- how the committee became  
9 more sophisticated, developed and was  
10 continuously improving itself.

11 QUESTIONS BY MS. CONROY:

12 Q. Would you agree that the one  
13 reason for the opioid crisis is oversupply of  
14 opioids in the United States?

15 MR. HOFFMAN: Object to form.  
16 Beyond the scope.

17 THE WITNESS: I believe that  
18 the opioid crisis -- very complicated,  
19 many, many factors there, so -- and I  
20 never -- I haven't studied it to say  
21 what are those specific factors and if  
22 that would be -- went into play.

23 QUESTIONS BY MS. CONROY:

24 Q. So you don't know if oversupply  
25 would be one factor?

1           A.       I can't comment on that.

2           Q.       Was the order monitoring  
3       committee set up in part to determine whether  
4       or not there was oversupply to a particular  
5       customer?

6                   MR. HOFFMAN: Object to the  
7       form.

8                   THE WITNESS: I was not with  
9       the company when they set up the order  
10      monitoring system.

11      QUESTIONS BY MS. CONROY:

12           Q.       Did you ever understand  
13      oversupply to a particular customer to be  
14      potentially a suspicious -- an indication of  
15      suspicion?

16                   MR. HOFFMAN: Object to form.

17                   THE WITNESS: I do recall in  
18      one instance, and I forget the name of  
19      the distributor, but it was tied to a  
20      pharmacy in Las Vegas, and I do recall  
21      that there was discussion about not  
22      about oversupply but overpurchasing by  
23      this particular wholesaler, and it  
24      appeared that a lot of the product was  
25      going to one particular pharmacy.

1 QUESTIONS BY MS. CONROY:

2 Q. So overpurchasing by a  
3 distributor that was then ultimately supplied  
4 to an individual pharmacy, would you call  
5 that oversupply?

6 A. I would call it a suspicious  
7 order.

8 Q. Suspicious because of its size?

9 A. Because of its size.

10 Q. Did the order monitoring  
11 committee ever stop any shipments of opioids?

12 A. I believe that there were  
13 certain instances where not the order  
14 monitoring team -- committee, but individuals  
15 or an individual that is a member of the  
16 team, based on a lot of this information,  
17 would at times produce orders to certain  
18 wholesalers.

19 Q. Did you ever, as an order  
20 monitoring committee member, reduce an order  
21 to a wholesaler?

22 A. No, I did not, because I did  
23 not have the authority to do so.

24 Q. Who did have the authority to  
25 do that?

1           A.       I -- as I recall, it was done  
2       by Stephen Seid.

3           Q.       Okay. And do you believe  
4       Stephen Seid, as a member of the order  
5       monitoring committee, reduced certain orders  
6       to wholesalers?

7           A.       I recall him doing it -- I  
8       recall there were instances where, in fact,  
9       he had done that.

10          Q.       Okay. And do you recall why he  
11       did that?

12          A.       Because the orders appeared to  
13       be suspicious.

14          Q.       Suspicious because of size?

15                 MR. HOFFMAN: Object to the  
16       form.

17                 THE WITNESS: Because either of  
18       size or because it became -- based on  
19       the algorithm, it looked unusual.

20       QUESTIONS BY MS. CONROY:

21          Q.       And he had the authority to do  
22       that on his own. That was not something that  
23       the order monitoring committee would vote on?

24          A.       I believe that he -- I don't  
25       believe it was the vote of the order

1 monitoring committee, but Steve Seid, whether  
2 he did on it on his own or had to receive  
3 approval from his management, is something  
4 I'm unaware of.

5 Q. But that was outside of -- as  
6 far as you know, the order monitoring  
7 committee never stopped any shipments of  
8 opioids?

9 MR. HOFFMAN: Object to the  
10 form.

11 THE WITNESS: The order  
12 monitoring committee was a monitoring  
13 committee, not responsible, or  
14 directly responsible, for the movement  
15 of product.

16 MS. CONROY: I think that's all  
17 I have. Thank you.

18 THE WITNESS: Thank you.

19 MR. LAFATA: Let's go off the  
20 record.

21 VIDEOGRAPHER: Okay. The time  
22 is 2:12 p.m. Off the record.

23 (Off the record at 2:12 p.m.)

24 VIDEOGRAPHER: The time is  
25 2:31. Back on the record.

1 CROSS-EXAMINATION

2 QUESTIONS BY MR. HOFFMAN:

3 Q. Mr. Geraci, good afternoon.

4 Again, for the record, my name  
5 is Nathan Hoffman. I represent Purdue, and  
6 now it's my chance to ask you a few  
7 questions.

8 Okay?

9 A. Okay.

10 Q. I promise to be brief. Thank  
11 you for your patience.

12 I'd like to go to Exhibit 9, if  
13 you have that in front of you. Just ask you  
14 a couple of clarifying questions.

15 And specifically, I'd like for  
16 you to turn to Slide Number 5, please.

17 A. (Witness complies.)

18 Q. Slide Number 5 is entitled,  
19 "OMS Information Sources." And you will see  
20 that the fourth bullet point in the slide  
21 describes a prescriber -- it says,  
22 "Prescriber program information."

23 Do you see that?

24 A. Yes, I do.

25 Q. And you were asked some

1 questions about that earlier, and I just want  
2 to clarify for the record.

3 What was the prescriber program  
4 at Purdue?

5 MS. CONROY: Objection.

6 THE WITNESS: In looking at  
7 this, I'm assuming that this is  
8 referring to the ADD program. I don't  
9 recall ever hearing it described as a  
10 prescriber program -- prescriber  
11 program information.

12 QUESTIONS BY MR. HOFFMAN:

13 Q. But as far as any distinction  
14 between, for example, order monitoring, the  
15 order monitoring system and a prescriber  
16 program, is the only prescriber program that  
17 you're aware of at Purdue, would that be the  
18 ADD program?

19 MS. CONROY: Objection.

20 THE WITNESS: That would be  
21 correct.

22 QUESTIONS BY MR. HOFFMAN:

23 Q. Okay. And you had some  
24 discussion about that earlier.

25 Is it true that the ADD program



1 was abuse, diversion and detection program?

2 A. Yes.

3 Q. And which department or  
4 departments were involved in the ADD program,  
5 if you know?

6 A. Legal department.

7 Q. So would that be a separate  
8 group analyzing that information as compared  
9 to the OMS committee?

10 A. That is correct.

11 Q. Okay. And then on the second  
12 page -- excuse me, not the second page, the  
13 next page, which is Slide 6, there is a title  
14 at the top of the slide. It says,  
15 "Prescriber versus Dispenser."

16 Do you see that?

17 A. Yes, I do.

18 Q. And does this slide, in fact,  
19 make a distinction between the prescriber  
20 program on the one hand and the OMS program  
21 on the other?

22 MS. CONROY: Objection.

23 THE WITNESS: Yes, it does.

24 QUESTIONS BY MR. HOFFMAN:

25 Q. And were you involved at all

1 directly in the ADD program versus your role  
2 in sitting on the OMS committee?

3 A. I was not directly involved in  
4 the ADD program.

5 Q. You were asked some questions  
6 by Ms. Conroy, I believe, to the effect of  
7 whether or not the OMS committee had the  
8 authority to stop or halt or change the  
9 orders that were being sent out to the  
10 wholesalers and distributors.

11 Do you recall that?

12 A. Yes, I do.

13 Q. Do you recall whether, in fact,  
14 the OMS committee at times provided guidance  
15 or input to committee members on the halting,  
16 changing or the volume of orders that were  
17 actually shipped to wholesalers and  
18 distributors?

19 MS. CONROY: Objection.

20 THE WITNESS: I don't -- I  
21 don't recall specifically, but it's  
22 reasonable that the committee would  
23 have provided guidance or  
24 recommendations to certain committee  
25 members concerning the distribution of

1 product to the distributors.

2 QUESTIONS BY MR. HOFFMAN:

3 Q. And would that be generally in  
4 the custom and practice of the committee to  
5 provide that type of guidance to its members?

6 MS. CONROY: Objection.

7 THE WITNESS: When appropriate.

8 QUESTIONS BY MR. HOFFMAN:

9 Q. And I believe you mentioned  
10 Mr. Seid earlier.

11 Is that who typically would be  
12 involved in those discussions?

13 A. He would be in those  
14 discussions and would in these -- in this  
15 instance would have been the recipient of  
16 that guidance and/or recommendation from the  
17 committee.

18 MR. HOFFMAN: Okay. Thank you.

19 I believe those are all the questions  
20 we have at this time.

21 MS. CONROY: I have a couple of  
22 follow-ups.

23 MR. HOFFMAN: Let me mark that  
24 real quick for the record, just before  
25 you come back over here. I forgot to

1 do this.

2 Just for the record, I'd like  
3 to mark as Exhibit 10 -- it's just our  
4 objection to the notice of deposition  
5 regarding the scope of the notice we  
6 received from plaintiff's counsel. I  
7 simply want to mark it for the record.  
8 I'm not going to ask any questions  
9 about it.

10 (Purdue-Geraci Exhibit 10  
11 marked for identification.)

12 REDIRECT EXAMINATION

13 QUESTIONS BY MS. CONROY:

14 Q. Mr. Geraci -- I'll wait until  
15 he get done. Sorry.

16 With respect to the ADD  
17 program, you said that the legal department  
18 would be the separate group that would  
19 analyze that information developed from the  
20 ADD program as opposed to the order  
21 monitoring committee?

22 A. Yes.

23 Q. But isn't it true that the  
24 order monitoring committee did have access to  
25 whatever analysis was done by the legal

1 committee of the ADD information?

2 A. I believe I testified to that  
3 already and said yes.

4 Q. Okay. So even though the  
5 analysis was done by the legal department,  
6 the order monitoring committee would be able  
7 to utilize that abuse, diversion -- abuse,  
8 detection and diversion information in its  
9 analysis of suspicious pharmacies?

10 A. Yes, it could.

11 Q. Your answers with respect to  
12 the questions about whether or not it would  
13 be -- whether or not you would have  
14 conversations among committee members with  
15 respect to the halting of product, do you  
16 recall that?

17 The question was: Do you  
18 recall whether, in fact, the OMS committee at  
19 times provided guidance or input to committee  
20 members on the halting, changing or the  
21 volume of orders that were actually shipped  
22 to wholesalers and distributors?

23 And you said you didn't recall  
24 specifically, but it was reasonable that the  
25 committee would have provided guidance or

1 recommendations to certain committee members  
2 concerning the distribution of product.

3 Do you recall that?

4 A. Yes.

5 Q. Do you have a memory of  
6 providing guidance, or are you testifying  
7 that it would have been reasonable for you to  
8 do that but you don't know if it ever  
9 happened?

10 MR. HOFFMAN: Object to the  
11 form.

12 THE WITNESS: I believe I also  
13 testified that I did recall an  
14 instance, one particular wholesaler,  
15 that had come to the attention of the  
16 committee and had been -- and that  
17 there was guidance provided, I believe  
18 it was guidance provided, or sales  
19 operations, Steve Seid, cut back  
20 orders to that particular wholesaler.  
21 I believe I did testify to that, in  
22 fact.

23 QUESTIONS BY MS. CONROY:

24 Q. Okay. So that was a particular  
25 incidence when Stephen Seid came to the

1 committee and talked to you about a  
2 particular order from a distributor, a  
3 particular size order?

4 A. What I stated was I don't  
5 recall how it came about, whether Steve Seid  
6 brought it to the committee's attention, or  
7 if this particular wholesaler and, of course,  
8 by extension, the pharmacy or pharmacies  
9 connected to it, had been under scrutiny by  
10 the OMS committee. I don't recall that.

11 But I do recall that there was  
12 an instance where orders to a particular  
13 wholesaler were, in fact, cut back.

14 Q. Do you have any particular --  
15 do you have any memory at all of discussing  
16 with committee members specific size orders  
17 that should be suspicious or a particular  
18 frequency of orders that should be suspicious  
19 or a particular pattern that should be  
20 suspicious?

21 MR. HOFFMAN: Object to the  
22 form.

23 THE WITNESS: I don't recall  
24 having that specific discussion.  
25

1 QUESTIONS BY MS. CONROY:

2 Q. Okay. What you do recall is  
3 when an actual order was described to you, as  
4 a committee member, that you commented on  
5 that particular order. And it was your  
6 recommendation, or at least the committee's  
7 recommendation, to Mr. Seid that that -- that  
8 order should not be shipped?

9 A. What I -- what I believe I  
10 stated just before was I don't recall the  
11 sequence of how it came to the committee's  
12 attention, what came first, but I do recall  
13 an instance where orders were cut back to a  
14 particular wholesaler.

15 Q. So if you don't recall the  
16 sequence, then you might remember that the  
17 committee decided a certain amount in an  
18 order should not be shipped, and then it's  
19 possible then that Mr. Seid said, "Oh, I have  
20 one of those"?

21 A. No, I don't recall it that way,  
22 and I don't recall that it was a particular  
23 size.

24 It was -- the one I'm referring  
25 to that I recall was -- and again, I don't



1 recall the sequence as to how it came about  
2 or came to the committee's attention, if it  
3 was sales, operation or national account,  
4 Mr. Seid seeing the pattern here, or if it  
5 was activity, investigative activity, that  
6 had been on -- under review by the OMS team.  
7 I just don't recall what came first.

8 And then I do recall that there  
9 was discussion and that there was a reduction  
10 in our sale of our product to this particular  
11 wholesaler.

12 Q. Do you recall the wholesaler?

13 A. If I recall correctly, I  
14 believe it was called Value Drug. I believe.

15 Q. And that was a wholesaler?

16 A. Yes.

17 Q. Is that a wholesaler that was  
18 part of the L.A. investigation?

19 A. L.A. investigation by whom?

20 Q. By the L.A. Times or -- there  
21 was a very large investigation. Jack Crowley  
22 was quoted in the newspaper.

23 Do you remember that?

24 A. I remember the L.A. Times  
25 articles. I don't recall specifically if

1 Valley Drug or whatever their name actually  
2 is or was mentioned in those articles. I  
3 just don't recall it.

4 Q. Okay. But you believe the  
5 wholesaler was Valley Drug?

6 A. I believe so.

7 Q. And is it your best memory that  
8 the order to Valley Drug was reduced?

9 A. To the best of my recollection,  
10 a order, or it could be orders, were in fact  
11 reduced.

12 Q. And what you don't recall is  
13 whether Valley Drug was already a subject of  
14 review by the order monitoring committee when  
15 this issue came up or whether someone brought  
16 it to the attention of the order monitoring  
17 committee?

18 A. That is correct.

19 Q. That's what you mean by  
20 sequence; you don't know whether the  
21 conversation started?

22 A. As I've stated repeatedly, yes,  
23 that is correct, I don't know what came  
24 first.

25 Q. Do you recall if there was a

1 discussion among the committee members as to  
2 what would constitute size, frequency or  
3 pattern that would require Mr. Seid to reduce  
4 the supply to Valley Drug?

5 MR. HOFFMAN: Object to the  
6 form.

7 THE WITNESS: I don't -- I  
8 don't recall those details.

9 QUESTIONS BY MS. CONROY:

10 Q. And that's the only instance  
11 you recall?

12 A. That's the only instance that I  
13 recall.

14 MS. CONROY: For completeness,  
15 let me mark the notice as well since  
16 you put the objection in.

17 We have a copy of the notice,  
18 right?

19 Do we?

20 MS. HURD: Oh, I don't know.

21 Yeah, it's here. Sorry.

22 MS. CONROY: That will be  
23 Exhibit 11.

24 (Purdue-Geraci Exhibit 11  
25 marked for identification.)

1 MS. CONROY: And I don't have  
2 any further questions. I just want to  
3 mark the exhibits.

4 THE WITNESS: Okay. Thank you.

5 MS. CONROY: Thank you.

6 VIDEOGRAPHER: Should we go off  
7 the record?

8 MR. HOFFMAN: That's fine.  
9 Yeah, we can mark it off the record.

10 VIDEOGRAPHER: Okay. This  
11 marks the end of today's deposition.  
12 The time is 2:46 p.m.

13 (Deposition concluded at 2:46 p.m.)

14 - - - - -

15

16

17

18

19

20

21

22

23

24


25

CERTIFICATE

I, CARRIE A. CAMPBELL, Registered  
Diplomate Reporter, Certified Realtime  
Reporter and Certified Shorthand Reporter, do  
hereby certify that prior to the commencement  
of the examination, Mark Geraci was duly  
sworn by me to testify to the truth, the  
whole truth and nothing but the truth.

I DO FURTHER CERTIFY that the  
foregoing is a verbatim transcript of the  
testimony as taken stenographically by and  
before me at the time, place and on the date  
hereinbefore set forth, to the best of my  
ability.

I DO FURTHER CERTIFY that I am  
neither a relative nor employee nor attorney  
nor counsel of any of the parties to this  
action, and that I am neither a relative nor  
employee of such attorney or counsel, and  
that I am not financially interested in the  
action.



CARRIE A. CAMPBELL,  
NCRA Registered Diplomate Reporter  
Certified Realtime Reporter  
Notary Public  
Dated: April 9, 2019

1 INSTRUCTIONS TO WITNESS

2

3 Please read your deposition over  
4 carefully and make any necessary corrections.  
5 You should state the reason in the  
6 appropriate space on the errata sheet for any  
7 corrections that are made.

8 After doing so, please sign the  
9 errata sheet and date it. You are signing  
10 same subject to the changes you have noted on  
11 the errata sheet, which will be attached to  
12 your deposition.

13 It is imperative that you return  
14 the original errata sheet to the deposing  
15 attorney within thirty (30) days of receipt  
16 of the deposition transcript by you. If you  
17 fail to do so, the deposition transcript may  
18 be deemed to be accurate and may be used in  
19 court.

20

21

22

23

24

25

ACKNOWLEDGMENT OF DEPONENT

I, \_\_\_\_\_, do  
hereby certify that I have read the foregoing  
pages and that the same is a correct  
transcription of the answers given by me to  
the questions therein propounded, except for  
the corrections or changes in form or  
substance, if any, noted in the attached  
Errata Sheet.

\_\_\_\_\_  
Mark Geraci

\_\_\_\_\_  
DATE

Subscribed and sworn to before me this  
\_\_\_\_\_ day of \_\_\_\_\_, 20 \_\_\_\_\_.

My commission expires: \_\_\_\_\_

Notary Public

1

- - - - -

ERRATA

2

- - - - -

3

PAGE

LINE

CHANGE/REASON

4

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

5

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

6

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

7

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

8

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

9

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

10

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

11

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

12

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

13

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

14

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

15

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

16

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

17

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

18

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

19

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

20

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

21

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

22

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

23

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

24

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

25



1  
  
2  
  
3  
  
4  
  
5  
  
6  
  
7  
  
8  
  
9  
  
10  
  
11  
  
12  
  
13  
  
14  
  
15  
  
16  
  
17  
  
18  
  
19  
  
20  
  
21  
  
22  
  
23  
  
24  
  
25

- - - - -

LAWYER'S NOTES

- - - - -

PAGE	LINE	
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____